Cell and Gene Therapy Trends for 2026: Navigating the Evolution of Advanced Therapeutics
By the end of 2026, the way we manufacture cell and gene therapies will look fundamentally different than it does today. Not because of scientific breakthroughs alone, but because operational realities are forcing a transformation that’s long overdue. The cell and gene therapy (CGT) landscape stands at a pivotal moment. With over 3,700 therapies in clinical and preclinical development and 76 products already launched globally, 2026 promises to be a defining year where innovation meets operational reality. For patient-centric organizations, CMOs, and CDMOs, understanding these emerging trends is not just about staying current, it’s about positioning your operations for sustainable …
How a Sample Inventory Management System Supports Scaling from Phase I to Commercialization
In the world of cell and gene therapy, growth is both the goal and the challenge. Early-stage biotech companies begin with a handful of samples, managed in spreadsheets and tracked manually. But what happens when your promising therapy enters Phase II, scales to multi-site trials, and eventually moves toward commercialization? The complexity of managing biological and cell therapy samples grows exponentially, and manual processes simply can’t keep up. This is where a scalable sample inventory system, implemented step by step becomes essential for managing biological and cell therapy samples. In this use case deep dive, we explore how the right …
